Tonix Pharmaceuticals Presents Promising TONMYA Data at International Fibromyalgia Congress

Tonix Pharmaceuticals Holding Corp. announced two oral presentations on TONMYA at the 8th International Congress on Controversies in Fibromyalgia held in Krakow, Poland. Post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies highlighted rapid pain relief and a favorable benefit-risk profile for TONMYA in adults with fibromyalgia. The data showed statistically significant reductions in pain and a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events.

TONMYA, the first medication approved for fibromyalgia in more than 15 years, was generally well tolerated, with mild and transient oral cavity reactions reported as the most common adverse events. This development matters significantly because fibromyalgia affects millions of people worldwide who have had limited treatment options for nearly two decades. The presentation of this data at an international scientific congress validates the medication's clinical profile and provides important information for healthcare providers considering treatment options for their patients.

The implications of this announcement extend beyond immediate pain relief for fibromyalgia patients. Tonix Pharmaceuticals is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. This suggests that the medication's mechanism of action may have broader applications in central nervous system disorders, potentially addressing multiple areas of high unmet medical need. The company's commercial infrastructure supports its marketed products, including its acute migraine products Zembrace SymTouch and Tosymra, positioning Tonix to effectively bring new treatments to market.

Tonix's broader pipeline includes additional central nervous system and immunology programs, such as TNX-2900 for Prader-Willi syndrome, monoclonal antibody TNX-4800 for Lyme disease prophylaxis, and TNX-1500 for preventing kidney transplant rejection. The company maintains a newsroom at https://ibn.fm/TNXP where investors can access the latest updates. The presentation of this data at an international congress represents an important milestone in validating TONMYA's clinical profile and expanding treatment options for fibromyalgia patients who have had limited new therapeutic alternatives for many years.